JP2024503379A5 - - Google Patents
Info
- Publication number
- JP2024503379A5 JP2024503379A5 JP2023541613A JP2023541613A JP2024503379A5 JP 2024503379 A5 JP2024503379 A5 JP 2024503379A5 JP 2023541613 A JP2023541613 A JP 2023541613A JP 2023541613 A JP2023541613 A JP 2023541613A JP 2024503379 A5 JP2024503379 A5 JP 2024503379A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sequence
- pharmaceutical composition
- fucosyl
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135479P | 2021-01-08 | 2021-01-08 | |
| US63/135,479 | 2021-01-08 | ||
| PCT/US2022/011564 WO2022150557A1 (en) | 2021-01-08 | 2022-01-07 | Combination therapy using an anti-fucosyl-gm1 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503379A JP2024503379A (ja) | 2024-01-25 |
| JP2024503379A5 true JP2024503379A5 (https=) | 2025-01-08 |
Family
ID=80119207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541613A Pending JP2024503379A (ja) | 2021-01-08 | 2022-01-07 | 抗フコシルｇｍ１抗体を使用した組み合わせ療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240050564A1 (https=) |
| EP (1) | EP4274850A1 (https=) |
| JP (1) | JP2024503379A (https=) |
| KR (1) | KR20230129467A (https=) |
| CN (1) | CN116745322A (https=) |
| AU (1) | AU2022205648A1 (https=) |
| CA (1) | CA3204392A1 (https=) |
| IL (1) | IL304200A (https=) |
| MX (1) | MX2023007780A (https=) |
| WO (1) | WO2022150557A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201912657D0 (en) * | 2019-09-03 | 2019-10-16 | Scancell Ltd | Binding members |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| US8383118B2 (en) | 2005-12-08 | 2013-02-26 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US11104739B2 (en) * | 2016-04-14 | 2021-08-31 | Bristol-Myers Squibb Company | Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody |
| CN109475634A (zh) * | 2016-06-03 | 2019-03-15 | 百时美施贵宝公司 | 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体 |
| RU2765997C2 (ru) * | 2017-03-30 | 2022-02-07 | Мерк Патент Гмбх | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования |
| MY205645A (en) * | 2018-06-23 | 2024-11-02 | Genentech Inc | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
-
2022
- 2022-01-07 MX MX2023007780A patent/MX2023007780A/es unknown
- 2022-01-07 EP EP22702075.7A patent/EP4274850A1/en active Pending
- 2022-01-07 US US18/271,579 patent/US20240050564A1/en active Pending
- 2022-01-07 CA CA3204392A patent/CA3204392A1/en active Pending
- 2022-01-07 JP JP2023541613A patent/JP2024503379A/ja active Pending
- 2022-01-07 CN CN202280009378.0A patent/CN116745322A/zh active Pending
- 2022-01-07 AU AU2022205648A patent/AU2022205648A1/en active Pending
- 2022-01-07 WO PCT/US2022/011564 patent/WO2022150557A1/en not_active Ceased
- 2022-01-07 KR KR1020237026366A patent/KR20230129467A/ko active Pending
-
2023
- 2023-07-03 IL IL304200A patent/IL304200A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020002171A5 (https=) | ||
| US11591406B2 (en) | Treatment for multiple myeloma (MM) | |
| JP2021523122A5 (https=) | ||
| JP2022548947A5 (https=) | ||
| JP2022525164A5 (https=) | ||
| JP2021528438A5 (https=) | ||
| JP2021535161A5 (https=) | ||
| JP2019524820A5 (https=) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2023520771A5 (https=) | ||
| IL320562A (en) | Cancer treatment methods | |
| JP2025512785A5 (https=) | ||
| JP2024517085A5 (https=) | ||
| JP2021530502A5 (https=) | ||
| JP2023524359A5 (https=) | ||
| JP2024503379A5 (https=) | ||
| JP2021532176A5 (https=) | ||
| JP2024521105A5 (https=) | ||
| JP2022514561A5 (https=) | ||
| JP2022513029A5 (https=) | ||
| JP2023500480A5 (https=) | ||
| Miyata et al. | Rebamipide enemas–new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis | |
| JP2023506779A5 (https=) | ||
| JP2022549218A5 (https=) | ||
| CN116113411A (zh) | 用于治疗软组织肉瘤的联用药物 |